Unlike poorly differentiated neuroendocrine carcinoma, G3 well-differentiated NET often does not respond to platinum plus etoposide (unless Ki-67 is quite high), and unlike well-differentiated G1-2 NET, G3 NET often does not express somatostatin receptors rendering SSAs and PRRT ineffective [2]. The gene discussed is MKI67; the disease is neuroendocrine carcinoma.